bioAffinity Technologies, Inc. announced on August 18, 2025, the appointment of Roberto Rios, CPA, and John J. Oppenheimer, M.D., to its Board of Directors. These appointments aim to provide significant financial and clinical expertise to support the company’s commercial growth.
Mr. Rios brings over four decades of executive leadership in corporate finance and governance across various industries, including biotechnology and medical devices. His experience in guiding companies through growth and capital strategy is expected to strengthen bioAffinity Technologies’ financial foundation.
Dr. Oppenheimer, a leader in asthma and COPD diagnosis and treatment, is the Director of Clinical Research at Pulmonary and Allergy Associates and a Clinical Professor of Medicine. His extensive clinical background will help guide the company’s scientific and clinical strategies, particularly in advancing companion diagnostics for the asthma therapeutics market. Gary Rubin also stepped down from the Board for personal reasons.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.